Compare BNTC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNTC | MYGN |
|---|---|---|
| Founded | 1995 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.9M | 372.1M |
| IPO Year | 2020 | 1996 |
| Metric | BNTC | MYGN |
|---|---|---|
| Price | $8.50 | $4.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 9 |
| Target Price | ★ $24.33 | $4.11 |
| AVG Volume (30 Days) | 192.6K | ★ 1.9M |
| Earning Date | 11-13-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $8.51 | $2.74 |
| 52 Week High | $16.76 | $8.59 |
| Indicator | BNTC | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 29.50 | 51.74 |
| Support Level | $8.52 | $2.89 |
| Resistance Level | $14.09 | $4.81 |
| Average True Range (ATR) | 0.64 | 0.23 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 12.90 | 8.27 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.